Designation of Methotrexate as an Orphan Drug - Ballia Holdings Pty Ltd

Overview

The Designation of Methotrexate as an Orphan Drug Gazette, published in 2013, was enacted to address the specific medical needs of children suffering from rare diseases such as Acute Lymphoblastic Leukaemia (ALL). This legislation was issued under the authority of the Therapeutic Goods Regulations 1990, administered by the Therapeutic Goods Administration (TGA) which is a part of the Australian Government's Department of Health. The policy objective behind this designation was to facilitate the development and availability of treatments for rare diseases by providing certain incentives, thus ensuring that life-saving medications are accessible to those who need them. The designation of Methotrexate as an orphan drug for this particular use underscores the commitment to improving paediatric healthcare and addressing the therapeutic gaps for children with severe and rare conditions.

Scope and Application

The Designation of Methotrexate as an Orphan Drug Act applies to the therapeutic agent Methotrexate, specifically for its use as an oral suspension in the treatment of Acute Lymphoblastic Leukaemia in children. The Act designates Methotrexate as an orphan drug under the Therapeutic Goods Regulations 1990, placing responsibility on the sponsor, Ballia Holdings Pty Ltd, for ensuring the drug meets the necessary regulatory standards for this particular use. The Act operates within the jurisdictional scope of the Commonwealth of Australia, affecting entities involved in the sponsorship, production, and distribution of the designated therapeutic goods. Notably, this Act does not outline specific exclusions or exemptions, nor does it mention thresholds for application, implying that its provisions apply universally to the designated drug and indication without further conditions. The Act also does not explicitly extend or restrict its application through subordinate instruments, leaving the interpretation and enforcement of its provisions within the broader framework of the Therapeutic Goods Regulations 1990.

Key Provisions

This legislation, C2013G00068, designates Methotrexate as an orphan drug under the Therapeutic Goods Regulations 1990 (section 16J). Specifically, section 16J(2) of the Regulations allows for the designation of orphan drugs for rare diseases or conditions, which in this case is Acute Lymphoblastic Leukaemia in children. The drug, Methotrexate, is to be administered in the form of an oral suspension. The sponsor responsible for this drug is Ballia Holdings Pty Ltd. The document, signed by Dr Anthony Gill, the Delegate of the Secretary, officially designates Methotrexate as an orphan drug for this specific use as of 14 December 2012. Under the Therapeutic Goods Regulations 1990, the designation of an orphan drug comes with specific obligations for the sponsor and the entities involved in the distribution and use of the drug. The sponsor, Ballia Holdings Pty Ltd, is responsible for ensuring that Methotrexate meets the regulatory standards set forth in the Act and Regulations. This includes ensuring that the drug is manufactured, labelled, and packaged in compliance with the required standards. The sponsor must also provide the necessary documentation and information to the Therapeutic Goods Administration (TGA) to support the orphan drug designation. Additionally, the sponsor is responsible for monitoring the drug’s safety and efficacy post-market and reporting any adverse effects to the TGA. The legislation does not explicitly outline specific offences, penalties, or civil/criminal consequences for breaches related to the orphan drug designation itself. However, the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 do provide for a range of enforcement actions for breaches of other regulatory requirements. These can include fines, imprisonment, or both, depending on the severity of the breach. For example, under section 34 of the Therapeutic Goods Act 1989, a person who contravenes the Act or Regulations can be fined up to $222,200 for an individual offence and $1,111,000 for a body corporate offence. In cases where the breach poses a significant risk to public health and safety, the penalties can be even more severe. Additionally, civil actions can be pursued for damages resulting from non-compliance. The Therapeutic Goods Administration has the authority to take enforcement actions to ensure compliance with the Act and Regulations, including issuing warning letters, imposing fines, and initiating legal proceedings where necessary.